PCI versus CABG versus medical therapy in 2006

Minerva Cardioangiologica

Volumn 54, Issue 5, 2006, Pages 643-672

  Morrison, D ^a  

^a Yakima Heart Center   (United States)

Author keywords

Coronary artery bypass; Coronary disease; Percutaneous, transluminal coronary angioplasty; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE; NICOTINIC ACID; NITRIC ACID DERIVATIVE; THIENOPYRIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; HEART MUSCLE ISCHEMIA; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; HUMANS; MYOCARDIAL ISCHEMIA;

EID: 33750702822     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (376)

1. Morrison DA, Serruys P, editors. Medically refractory rest angina. New York, NY: Marcel Dekker, Inc.; 1992.
2. Morrison DA, Serruys P, editor. High risk cardiac revascularization and clinical trials. London: Martin Dunitz; 2002.
3. Morrison DA, Sacks J. Balancing benefit against risk in the choice of therapy for coronary artery disease. Lesson from prospective, randomized, clinical trials of percutaneous coronary intervention and coronary artery bypass graft surgery. Minerva Cardioangiol 2003;51:585-97.
4. Morrison DA. The epidemiology of high-risk coronary artery and the choice between stents and surgery. Dissertation for the PhD in Epidemiology, University of Arizona; 2004.
5. Morrison DA. Multivessel percutaneous coronary intervention: a new paradigm for a new century. Minerva Cardioangiol 2005;53:361-77.
6. Guidelines and indications for coronary artery bypass graft surgery. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 1991;17:543-89.
7. Eagle KA, Guyton RA, Davidoff R, Ewy GA, Fonger J, Gardner TJ et al. ACC/AHA guidelines for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 1999;34:1262-346.
8. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Thoracic Surgery and the Society of Thoracic Surgeons. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110:1168-76.
9. Erratum in: Circulation 2005;111:2014.
10. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1993;22:2033-54.
11. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines): executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001;37:2215-39.
12. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention). Catheter Cardiovasc Interv 2006;67:87-112.
13. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-428.
14. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
15. Braunwald E, Amman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36:970-1062.
16. Erratum in: J Am Coll Cardiol 2001;38:294-5.
17. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS et al.; American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-74.
18. Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 1988;319:332-7.
19. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation 1983;68:939-50.
20. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344:563-70.
21. Erratum in: Lancet 1994;344:1446.
22. Peduzzi P, Kamina A, Detre K. Twenty-two-year follow-up in the VA Cooperative Study of Coronary Artery Bypass Surgery for Stable Angina. Am J Cardiol 1998;81:1393-9.
23. Killip T, Passamani E, Davis K. Coronary artery surgery study (CASS): a randomized trial of coronary bypass surgery. Eight years follow-up and survival in patients with reduced ejection fraction. Circulation 1985;72(6 Pt 2):V102-9.
24. Alderman EL, Bourassa MG, Cohen LS, Davis KB, Kaiser GG, Killip T et al. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation 1990;82:1629-46.
25. Takaro T, Peduzzi P, Detre KM, Hultgren HN, Murphy ML, van der Bel-Kahn J et al. Survival in subgroups of patients with left main coronary artery disease. Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive Disease. Circulation 1982;66:14-22.
26. Califf RM, Harrell FE Jr, Lee KL, Rankin JS, Hlatky MA, Mark DB et al. The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspective. JAMA 1989;261:2077-86.
27. Sharma GV, Deupree RH, Khuri SF, Parisi AF, Luchi RJ, Scott SM. Coronary bypass surgery improves survival in high-risk unstable angina. Results of a Veterans Administration Cooperative study with an 8-year follow-up. Veterans Administration Unstable Angina Cooperative Study Group. Circulation 1991;84(5 Suppl):III260-7.
28. Luchi RJ, Scott SM, Deupree RH. Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study. N Engl J Med 1987;316:977-84.
29. Scott SM, Luchi RJ, Deupree RH. Veterans Administration Cooperative Study for treatment of patients with unstable angina. Results in patients with abnormal left ventricular function. Circulation 1988;78(3 Pt 2):I113-21.
30. Parisi AF, Khuri S, Deupree RH, Sharma GVRK, Scott SM, Luchi RJ. Medical compared with surgical management of unstable angina 5-year mortality and morbidity in the Veterans Administration Study. Circulation 1989;80:1176-89.
31. Unstable angina pectoris: national cooperative study group to compare medical and surgical therapy. I. Report of protocol and patient population. Am J Cardiol 1976;37:896-902.
32. Unstable angina pectoris: National Cooperative Study Group to Compare Surgical and Medical Therapy. Am J Cardiol 1978;42:839-48.
33. Unstable angina pectoris: national cooperative study group to compare surgical and medical therapy. III. Results in patients with S-T segment elevation during pain. Am J Cardiol 1980;45:819-24.
34. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med 1992;326:10-6.
35. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997;350:461-8.
36. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70-6.
37. Bourassa MG, Knatterud GL, Pepine CJ, Sopko G, Rogers WJ, Geller NL et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. Improvement of cardiac ischemia at 1 year after PTCA and CABG. Circulation 1995;92(9 Suppl):II1-7.
38. TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomized trial Lancet 2001;358:951-7.
39. Pfisterer M, Buser P, Osswald S, Allemann U, Amann W, Angehrn W et al.; Trial of Invasive versus Medical therapy in Elderly patients (TIME) Investigators. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003;289:1117-23.
40. Pfisterer M; Trial of Invasive versus Medical therapy in Elderly patients Investigators. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation 2004;110:1213-8.
41. King SB III, Schlumpf M. Ten-year completed follow-up of percutaneous transluminal coronary angioplasty: the early Zurich experience. J Am Coll Cardiol 1993;22:353-60.
42. Cowley MJ, Vetrovec GW, DiSciascio G, Lewis SA, Hirsch PD, Wolfgang TC. Coronary angioplasty of multiple vessels: short term outcome and long-term results. Circulation 1985;72:1314-20.
43. Cesar LA, Hueb WA. The MASS trials. In: Morrison DA, Serruys PW, editors. High-risk cardiac revascularization and clinical trials. London: Martin Dunitz; 2002.p.203-16.
44. Lembo NJ, King SB III. Randomized trials of percutaneous transluminal coronary angioplasty, coronary artery bypass grafting surgery, or medical therapy in patients with coronary artery disease. Cor Art Dis 1990;1:449-454.
45. RITA Trial Participants. Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet 1993;341:573-80.
46. CABRI Trial Participants. First Year Results of CABRI (Coronary Angioplasty vs Bypass Revascularization Investigation). Lancet 1995;346:1179-84.
47. King SB 3rd, Lembo NJ, Weintraub WS, Kosinski AS, Barnhart HX, Kutner MH et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994;331:1044-50.
48. Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med 1994;331:1037-43.
49. Rodriguez A, Boullon F, Perez-Balino N, Paviotti C, Liprandi MI, Palacios IF. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. J Am Coll Cardiol 1993;22:1060-7.
50. BARI Investigators: Protocol for the Bypass Angioplasty Revascularization Investigation. Circulation 1991;84 Suppl V:1-27.
51. Frye RL, King SB III, Sopko G, Detre KM. A Symposium: Multi-vessel PTCA versus CABG: baseline data from the Bypass Angioplasty Revascularization Investigation (BARI) and the Emory Angioplasty Surgery Trial (EAST). Am J Cardiol 1995;75:1c-59c.
52. Pocock SJ, Henderson RA, Rickards AF, Hampton JR, King SB III, Hamm CW et al. Meta-analysis of randomized trials comparing coronary angioplasty with bypass surgery. Lancet 1995;346:1184-9.
53. Sim I, Gupta M, McDonald K, Bourassa M, Hlatky MA. A meta-analysis of randomized trials comparing coronary artery bypass grafting with percutaneous transluminal coronary angioplasty in multi-vessel coronary artery disease. Am J Cardiol 1995;76:1025-9.
54. King SB 3rd, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 2000;35:1116-21.
55. Henderson RA, Pocock SJ, Sharp SJ, Nanchahal K, Sculpher MJ, Buxton MJ et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina. Lancet 1998;352:1419-25.
56. CABRI Trial Participants. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation). Lancet 1995;346:1179-84.
57. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-25.
58. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000;35:1122-9.
59. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1995;308:81-106.
60. Lewis RD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty J et al. Protective effect of aspirin against acute myocardial infarction and death in men unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309:396-403.
61. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-75.
62. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-1339.
63. The Clopidogrel in Unstable angina to Prevent Recurrent Events Trial Investigators: Effects of Clopidogrel I addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
64. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease II. Unstable Angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-63.
65. Larosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM Jr et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1998;97:946-52.
66. Report from the Committee of Principal Investigators. A cooperative trial in the primary prevention of ischémie heart disease using clofibrate. Br Heart J 1978;40:1069-118.
67. The Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1979;60:427-39.
68. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
69. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
70. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-age men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
71. Mannihen V, Elo O, Frick MH, Haapa K, Heinonen OP, Heinsalmi P et al. Lipid alterations and decline in incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
72. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
73. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
74. Rubins HB, Robins S, Collins D, Fye CL, Anderson JW, Elam MB et al. for the Veterans Affairs High-density lipoprotein Cholesterol Intervention trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.
75. Rubins HB, Robins SJ, Collins D. The Veterans Affairs high-density lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Card 1996;78:572-5.
76. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223;405-18.
77. Shepherd J, Cobbe SM, Ford I, Lsles CG, Lorimer AR, Macfarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
78. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS. JAMA 1998;279:1615-22.
79. Scandanavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-9.
80. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Ruther JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
81. The Long-Term Intervention With Pravastatin in Ischaemic Disese (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
82. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
83. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57-66.
84. The MIAMI Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled intervention trial. Eur Heart J 1985;6:199-226.
85. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC et al. for the TIMI Investigators: Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991;83:422-37.
86. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981;2:823-7.
87. The International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 1984;310:9-15.
88. Norris RM, Clarke ED, Sammel NL, Smith WM, Williams B. Protective effect of propranolol in threatened myocardial infarction. Lancet 1978;2:907-9.
89. Yusuf S, Ramsdale D, Peto R, Furse L, Bennett D, Bray C et al. Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Lancet 1980;2:273-6.
90. Yusuf S, Sleight P, Rossi P, Ramsdale D, Peto R, Furze L et al. Reduction in Infarct size, arrhythmias and chest pain by early intravenous beta-blockade in suspected acute myocardial infarction. Circulation 1983;67:132-141.
91. Ramsdale DR, Faragher EB, Bennett DH, Bray CL, Ward C, Cruickshank JM et al. Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. Am Heart J 1982;103:459-67.
92. Richterova A, Herlitz J, Holmberg S, Swedberg K, Waagstein F, Waldenstrom A et al. Goteborg Metoprolol Trial: effects on chest pain. Am J Cardiol 1984;53:32D-36D.
93. Waagstein F, Hjalmarson A. Double-blind study of the effect of cardioselective beta-blockade on chest pain in acute myocardial infarction. Acta Med Scand 1975;Suppl 587:201-8.
94. Basu S, Senior R, Raval U, Raval U, van der Does R, Bruckner T et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction, a placebo-controlled randomized trial. Circulation 1997;96:183-91.
95. Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction I. Mortality results. JAMA 1982;247:1707-14.
96. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J 1987;8:1056-64.
97. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
98. Pederson TR for the Norwegian Multicenter Study Group. Six-year follow-up of the norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med 1985;313:1055-8.
99. Olsson G, Rehnqvist N, Sjogren A, Erhardt L, Lundman T. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 1985;5:1428-37.
100. Olsson G, Oden A, Johansson L, Sjogren A, Rehnqvist N. Prognosis after withdrawal of chronic post infarction metoprolol treatment: a 2-7 year follow-up. Eur Heart J 1988;9:365-72.
101. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
102. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE et al. for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
103. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-50.
104. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
105. Persson H, Eriksson SV, Erhardt L. Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction, a double-blind comparison of metoprolol and xamoterol. Eur Heart J 1996;17:741-9.
106. Persson H, Rythe-Adler E, Erhardt L. Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double-blind comparison of metoprolol with xamoterol. Br Heart J 1995;74:140-8.
107. Waagstein F, Bristow M, Swedborg K, Camerini F, Fowler MB, Silver MA et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
108. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
109. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I et al. for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure the PRECISE trial. Circulation 1996;94:2793-9.
110. Australia-New Zealand Heart Failure Research Collaborative Group, Effects of Carvedilol, a vasodilator-beta blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-8.
111. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-12.
112. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
113. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
114. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
115. Chinese Cardiac Study Collaboration Group. Oral captopril versus placebo among 13,634 patients with suspect acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS 1). Lancet 1995; 345:686.
116. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995;92:3132-7.
117. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. J Am Coll Cardiol 1996;27:337-44.
118. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997;96:4239-45.
119. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
120. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-6.
121. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342: 821-8.
122. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997;349:1493-7.
123. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
124. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
125. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
126. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
127. Erratum in: N Engl J Med 1992;327:1768.
128. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. Br Heart J 1992;67:289-96.
129. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
130. DeWood MA, Stifter WF, Simpson CS, Spores J, Eugster GS, Judge TP et al. Coronary angiographic findings soon after non-Q myocardial infarction. N Engl J Med 1986;315:417-23.
131. Fibrinolytic Therapy Trialists' (FTT) collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311-22.
132. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003;361:13-20.
133. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-4.
134. Ribeiro EE, Silva LA, Carneiro R, D'Oliveira LG, Gasquez A, Amino JG et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1993;22:376-80.
135. Grinfeld L, Berrocal D, Belardi J, Spinetta A, Matas CR, Oberti P et al. Fibrinolytics vs. primary angioplasty in acute myocardial infarction (FAP). J Am Coll Cardiol 1996;27 Suppl:A222.
136. Zijlstra F, Beukema WP, van't Hof AW, Liem A, Reiffers S, Hoorntje JC et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1997;29:908-12.
137. Akhras F, Abu Ousa A, Swann G, Duncan H, Chamsi-Pasha H, Jabbad H. Primary coronary angioplasty or intravenous thrombolysis for patients with acute myocardial infarction? Acute and late follow-up results in a cardiac care unit. J Am Coll Cardiol 1997;29 Suppl:A235-6.
138. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000;21:823-31.
139. de Boer MJ, Ottervanger JP, van'tHof AW, Hoorntje JC, Suryapranata H, Zijlstra F. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002;39:1723-8.
140. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-9.
141. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med 1993;328:685-91.
142. Ribichini F, Steffenino G, Dellavalle A, Ferrero V, Vado A, Feola M et al. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study. J Am Coll Cardiol 1998;32:1687-94.
143. Garcia E, Elizaga J, Perez-Castellano N, Serrano JA, Soriano J, Abeytua M et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol 1999;33:605-11.
144. The Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-8.
145. Le May MR, Labinaz M, Davies RF, Marquis JF, Laramee LA, O'Brien ER et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardiol 2001;37:985-91.
146. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY et al.; Comparison of Angioplasty and Prehospital Thromboysis in Acute Myocardial Infarction study group. Primary angioplasty versus prehospital filbrinolysis in acute myocardial infarction: a randomised study. Lancet 2002;360:825-9.
147. Schomig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000;343:385-91.
148. Vermeer F, Oude Ophuis AJ, vd Berg EJ, Brunninkhuis LG, Werter CJ, Boehmer AG et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999;82:426-31.
149. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P et al.; DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-42.
150. Kastrati A, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J et al.; Stent versus Thrombolysis for Occluded Coronary Arteries in Patients With Acute Myocardial Infarction (STOPAMI-2) Study. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet 2002;359:920-5.
151. Aversano T, Aversano LT, Passamani E, Knatterud GL, Terrin ML, Williams DO et al.; Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT). Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002;287:1943-51.
152. Erratum in: JAMA 2002;287:3212.
153. Grines CL, Westerhausen DR Jr, Grines LL, Hanlon JT, Logemann TL, Niemela M et al.; Air PAMI Study Group. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002;39:1713-9.
154. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999;341:625-34.
155. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997;278:2093-8.
156. Erratum in: JAMA 1998;279:1876.
157. Every NR, Maynard C, Cochran RP, Martin J, Weaver WD, for the Myocardial Infarction Triage and Intervention Investigators. Characteristics, management, and outcome of patients treated with acute myocardial infarction treated with bypass surgery. Circulation 1996;94 Suppl II:II-81-6.
158. Stone GW, Brodie BR, Grines L, Boura J, O'Neill WW, Grines CL for the Primary Angioplasty in Myocardial Infarction Trial-2 (PAMI-2) Investigators. Role of cardiac surgery in the hospital phase of management of patients treated with primary angioplasty for acute myocardial infarction. Am J Cardiol 2000;85:1292-6.
159. Braunwald E. Unstable angina: a classification. Circulation 1989;80:410-4.
160. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-q-wave myocardial infarction. Circulation 1994;89:1545-56.
161. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338:1785-92.
162. Erratum in: N Engl J Med 1998;339:1091.
163. FRagmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:708-15.
164. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N et al.; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
165. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR et al. Randomized Intervention Trial of unstable Angina Investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002;360:743-51.
166. Fischman DL, Savage MP, Leon MB, Schatz RA, Ellis SG, Cleman MW et al. Effect of intracoronary stenting on intimai dissection after balloon angioplasty: results of quantitative and qualitative coronary analysis. J Am Coll Cardiol 1991;18:1445-51.
167. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographice and therapeutic profile. J Am Coll Card 1992;19:926-35.
168. Lincoff AM, Topol EJ, Chapekis AT, George BS, Candela RJ, Muller DWM et al. Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty: a matched case-control study. J Am Coll Cardiol 1993;21:866-75.
169. Alfonso F, Hernandez R, Goicolea J, Segovia J, Perez-Vizcayano MJ, Banuelos C et al. Coronary stenting for acute coronary dissection after coronary angioplasty: implications of residual dissection. J Am Coll Cardiol 1994;24:989-95.
170. Colombo A, Goldberg SL, Almagor Y, Maiello L, Finci L. A novel strategy for stent deployment in the treatment of acute or threatened closure complicating balloon coronary angioplasty. J Am Coll Cardiol 1993;22:1887-91.
171. Bergelson BA, Fishman RF, Tommasso CL. Abrupt vessel closure: changing importance, management and consequences. Am Heart J 1997;134:362-81
172. George BS, Voorhees WD 3rd, Roubin GS, Fearnot NE, Pinkerton CA, Raizner AE et al. Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographie outcomes. J Am Coll Cardiol 1993;22:135-43.
173. Wong SC, Baim DS, Schatz RA, Teirstein PS, King SB 3rd, Curry RC Jr et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group. J Am Coll Cardiol 1995;26:704-12.
174. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al. A comparison of balloon-expandable-stent implantation with balloon angiopksty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95.
175. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
176. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al; SIRIUS Investigators. Sirolimus-eluting stems versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
177. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al.; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
178. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet 2004;364:583-91.
179. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-5.
180. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Fache J et al.; ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293;165-71.
181. Lemos PA, Lee CH, Degertekin M, Saia F, Tanabe K, Arampatzis CA et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003;41:2093-9.
182. Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004;43:704-8.
183. Saia F, Lemos PA, Lee CH, Arampatzis CA, Hoye A, Degertekin M et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study. Circulation 2003;108:1927-9.
184. Hoye A, Lemos PA, Arampatzis CA, Saia F, Tanabe K, Degertekin M et al. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004;16:230-3.
185. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 2005;45:989-94.
186. Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45:1135-41.
187. Hoye A, Tanabe K, Lemos PA, Aoki J, Saia F, Arampatzis C et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol 2004;43:1954-8.
188. Kereiakes DJ. Platelet glycoprotein IIb/IIa Inhibition and atheroembolism during bypass graft angioplasty A cup Half Full. Circulation 2002;106:2994-6.
189. Karvounni E, Katritsis DG, Ionnidis JPA. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Card 2003;41:26-32.
190. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl Med 1994;330:956-61.
191. EPILOG Investigators. Platelet glycoprotein IIb/IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization. N Engl Med 1997;336:1689-96.
192. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
193. IMPACT II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422-8.
194. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
195. CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
196. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-41.
197. Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1998;32:28-34.
198. Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-22.
199. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
200. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71.
201. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998;98: 1597-603.
202. Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998;98:2126-32.
203. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW et al. Meta-analysis or randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14.
204. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-88.
205. Nakamura S, Hall P, Gaglione A, Tiecco F, Di Maggio M, Maiello L et al. High pressure assisted coronary stent implantation accomplished without intravascular ultrasound guidance and subsequent anticoagulation. J Am Coll Cardiol 1997;29:21-7.
206. Karrillon GJ, Morice MC, Benveniste E, Bunouf P, Aubry P, Cattan S et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation 1996;94:1519-27.
207. Moussa I, DiMario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 1997;29:6-12.
208. Holmes DR Jr, Garratt KN, Popma J. Stent complications. J Invasive Cardiol 1998;10:385-395.
209. Orford JL, Lennon R, Melby S, Fasseas P, Bell MR, Rihal CS et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol 2002;40:1567-72.
210. Morrison DA, Barbiere CC, Johnson R, Marshall G, Fullerton D, Hammermeister KE et al. Salvage angioplasty: an alternative to high-risk surgery for unstable angina. Cathet Cardiovasc Diagn 1992;27:169-78.
211. Morrison DA, Sacks J, Grover F, Hammermeister K. Effectiveness of percutaneous transluminal coronary angioplasty for patients with medically refractory rest angina pectoris and high risk of adverse outcomes with coronary artery bypass grafting. Am J Card 1995;75:237-40.
212. Morrison DA. Summary of "high risk" and "prohibitive risk" for surgery or angioplasty in unstable angina. In: Morrison DA, Serruys PW, editors. Medically refractory rest angina. New York: Marcel Dekker; 1992.p.385-401.
213. Morrison DA, Sacks J, Barbiere CC, Sethi G. PTCA comes to the bifurcations in the road: what the VA has to offer. J Am Coll Cardiol 1997;29:1512-4.
214. Tan K, Sulke N, Taub N, Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience. J Am Coll Cardiol 1995;25:855-65.
215. Saucedo JF, Popma JJ, Kennard ED, Talley DJ, Lansky A, Leon MB et al. for the NACI Investigators. Relation of Coronary Artery size to One-year Clinical Events after New Device Angioplasty of native Coronary Arteries (A New Approach to Coronary Intervention [NACI] Registry Report). Am J Cardiol 2000;85:166-71.
216. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990;82:1193-202.
217. Mathew V, Grill DE, Scott CG, Garrettt KN, Holmes DR Jr. Baseline clinical and angiographic variables associated with long-term outcome after successful intracoronary stent implantation. Am J Cardiol 1999;84:789-94.
218. Krone RJ, Laskey WK, Johnson C, Kimmel SE, Klein LW, Weiner BH et al. for the Registry Committee of the Society for Cardiac Angiography and Interventions. A simplified lesion classification for predicting success and complications of coronary angioplasty. Am J Cardiol 2000;85:1179-84.
219. Krone RJ, Kimmel SE, Laskey WK, Klein LW, Schectman KB, Constentino AJJ et al. for the Registry Committee of the Society for Cardiac Angiography and Interventions. Evaluation of the Society for Cardiac Angiography and Interventions' lesion classification system in 14,133 patients with percutaneous coronary interventions in the current stent era. Catheter Cardiovasc Interv 2002;55:1-7.
220. Wilensky RL, Selzer F, Johnston J, Laskey WK, Klugherz BD, Block P et al. Relation of percutaneous coronary intervention of complex lesions to clinical outcomes (from the NHLBI Dynamic Registry). Am J Cardiol 2002;90:216-21.
221. Wong P, Lau KW, Lim YL, Oesterle SN. Catheterization curriculum: stent placement for non-STRESS/BENESTENT lesions: a critical review Catheter Cardiovasc Interv 2000;51:223-33.
222. Koning R, Eltchaninoff H, Commeau P, Khalife K, Guard M, Lipiecki J et al.; BESMART (BeStent in Small Arteries) Trial Investigators. Stent placement compared with balloon angioplasty for small coronary arteries: in-hospital and 6-month clinical and angiographic results. Circulation 2001;104:1604-8.
223. Kastrati A, Schomig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N et al. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary stenting or angioplasty for restenosis reduction in small arteries. Circulation 2000;102:2593-8.
224. Savage MP, Fischman DL, Rake R, Leon MB, Schatz RA, Penn I et al. Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries. Stent Restenosis Study (STRESS) Investigators. J Am Coll Cardiol 1998;31:307-11.
225. Akiyama T, Moussa I, Reimers B, Ferraro M, Kobayashi Y, Blengino S et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol 1998;32:1610-8.
226. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875-80.
227. Al Suwaidi J, Yeh W, Williams DO, Laskey WK, Cohen HA, Detre KM et al. Comparison of immediate and one-year outcome after coronary angioplasty of narrowing <3 mm with those > or =3 mm (the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2001;87:680-6.
228. Kornowski R, Bhargava B, Fuchs S, Lansky AJ, Satler LF, Pichard AD et al. Procedural results and late clinical outcomes after percutaneous interventions using long (> or =25 mm) versus short (<20 mm) stents. J Am Coll Cardiol 2000;35:612-8.
229. Briguori C, Nishida T, Adamian M, Albiero R, Anzuini A, Di Mario C et al. Coronary stenting versus balloon angioplasty in small coronary artery with complex lesions. Catheter Cardiovasc Interv 2000;50: 390-7.
230. Lemos PA, Martinez EE, Quintella E, Harrell LC, Ramires JA, Ribeiro EE et al. Stenting vs. balloon angioplasty with provisional stenting for the treatment of vessels with small reference diameter. Catheter Cardiovasc Interv 2002;55:309-14.
231. Goudreau E, DiSciasio G, Kelly K, Vetrovec GW, Cowley MJ. Coronary angioplasty of diffuse coronary artery disease. Am Heart J 1991;121:12-9.
232. Antonucci D, Valenti R, Santoro GM, Bolognese L, Trapani M, Fazzini PF. Preliminary experience with stent-supported coronary angioplasty in long narrowings using the long freedom force stent. Catheter Cardiovasc Interv 1998;43:163-7.
233. Schalij MJ, Udayachalerm W, Oemrawsingh P, Jukema JW, Reiber JH, Bruschke AV. Stenting of long coronary artery lesions: initial angiographic results and 6-month clinical outcome of the micro stent II-XL. Catheter Cardiovasc Interv 1999;48:105-12.
234. Kobayashi Y, De Gregorio J, Kobayashi N, Akiyama T, Reimers B, Find L, Di Mario C, Colombo A. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999;34:651-9.
235. Di Sciasio G, Patti G, Nasso G, Manzoli A, D'Ambrosio A, Abbate A. Early and long-term results of stenting diffuse coronary artery disease. Am J Cardiol 2000;86: 1166-70.
236. Tuzcu EM, Berkalp B, De Franco AC, Ellis SG, Goormastic M, Whitlow PL et al. The dilemma of diagnosing coronary calcification: angiography versus intravascular ultrasound. J Am Coll Cardiol 1996;27: 832-8.
237. Warth DC, Leon MB, O'Neill W, Zacca N, Polissar NL, Buchbinder M. Rotational Atherectomy Multicenter Registry: acute results and 6-month angiographic follow-up in 709 patients. J Am Coll Cardiol 1994;24: 641-8.
238. Hoffmann R, Mintz GS, Kent KM, Pichard AD, Satler LF, Popma JJ, Hong MK, Laird JR, Leon MB. Comparative early and nine-month results of rotational atherectomy, stents, and the combination of both for calcified lesions in large coronary arteries. Am J Cardiol 1998;81:552-7.
239. Litvack F, Eigler N, Margolis J, Rothbaum D, Bresnahan JF, Holmes D et al. Percutaneous excimer laser coronary angioplasty: results in the first consecutive 3,000 patients. The ELCA Investigators. J Am Coll Cardiol 1994;23:323-9.
240. Ahmed W, Al-Anazi MM, Bittl JA. Excimer Laser-facilitated angioplasty for undilatable coronary narrowing. Am J Cardiol 1996;78:1045-7.
241. Vetrovec GW, Cowley MJ, Wolfgang TC, Ducey KC. Effects of percutaneous transluminal coronary angioplasty on lesion-associated branches. Am Heart J 1985;109:921-5.
242. Pinkerton CA, Slack JD, Van Tassel JW, Orr CM. Angioplasty for dilatation of complex coronary artery bifurcation stenoses. Am J Cardiol 1985;55(13 Pt 1):1626-8.
243. Meier B. Kissing balloon coronary angioplasty. Am J Cardiol 1984;54:918-20.
244. Al Suwaidi J, Yeh W, Cohen HA, Detre KM, Williams DO, Holmes DR Jr. Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry). Am J Cardiol 2001;87:1139-44.
245. George BS, Myler RK, Stertzer SH, Clark DA, Cote G, Shaw RE et al. Balloon angioplasty of coronary bifurcation lesions: the kissing balloon technique. Cathet Cardiovasc Diagn 1986;12:124-38.
246. Myler RK, McConahay DR, Stertzer SH, Johnson W, Cumberland DC, Boucher RA et al. Coronary bifurcation stenoses: the kissing balloon Probe technique via a single guiding catheter. Cathet Cardiovasc Diagn 1989;16:267-78.
247. Colombo A, Gaglione A, Nakamura S, Finci L. "Kissing" stents for bifurcational coronary lesion. Cathet Cardiovasc Diagn 1993;30:327-30.
248. Nakamura S, Hall P, Maiello L, Colombo A. Techniques for Palmaz-Schatz stent deployment in lesions with a large side branch. Cathet Cardiovasc Diagn 1995;34:353-61.
249. Satler LF, Mintz GS, Pichard AD, Kont KM. Bifurcation disease: to treat or not to treat. Catheter Cardiovasc Interv 2000;50:411-2.
250. Colombo A, Stankovic G, Orlic D, Corvaja N, Liistro F, Airoldi F et al. Modified T-stenting technique with crushing for bifurcation lesions: immediate results and 30-day outcome. Catheter Cardiovasc Interv 2003;60:145-51.
251. Caputo RP, Chafizadeh ER, Stoler RC, Lopez JJ, Cohen DJ, Kuntz RE et al. Stent jail: a minimum-security prison. Am J Cardiol 1996;77:1226-9.
252. Al Suwaidi J, Berger PB, Rihal CS, Garratt KN, Bell MR, Ting HH et al. Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. J Am Coll Cardiol 2000;35:929-36.
253. Chevalier B, Glatt B, Royer T, Guyon P. Placement of coronary stents in bifurcation lesions by the 'culotte' technique. Am J Cardiol 1998;82:943-9.
254. Carrie D, Elbaz M, Dambrin G, Saint-Cricq F, Dugrand P, Fourcade J et al. Coronary stenting of bifurcation lesions using "T" or "reverse Y" configuration with Wiktor stent. Am J Cardiol 1998;82:1418-21, A8.
255. DiMario C, Colombo A. Trousers-stents: how to choose the right size and shape? Catheter Cardiovasc Interv 1997;41:197-9.
256. Aliabadi D, Tilli FV, Bowers TR, Benzuly KH, Safian RD, Goldstein JA et al. Incidence and angiographic predictors of side branch occlusion following high-pressure intracoronary stenting. Am J Cardiol 1997;80:994-7.
257. Yamashita T, Nishida T, Adamian MG, Briguori C, Vaghetti M, Corvaja N et al. Bifurcation lesions: two stents versus one stent: immediate and follow-up results. J Am Coll Cardiol 2000;35:1145-51.
258. Hoye A, van der Giessen WJ. New approaches to ostial and bifurcation lesions. J Interv Cardiol 2004;17:397-403.
259. Sharma SK, Choudhury A, Lee J, Kim MC, Fisher E, Steinheimer AM et al. Simultaneous kissing stents (SKS) technique for treating bifurcation lesions in medium-to-large size coronary arteries. Am J Cardiol 2004;94:913-7.
260. Kobayashi Y, Colombo A, Adamian M, Nishida T, Moussa I, Moses JW. The skirt technique: a stenting technique to treat a lesion immediately proximal to the bifurcation (pseudobifurcation). Catheter Cardiovasc Interv 2000;51:347-51.
261. Carrie D, Karouny E, Chouairi S, Fuel J. "T"-shaped stent placement: a technique for the treatment of dissected bifurcation lesions. Cathet Cardiovasc Diagn 1996;37:311-3.
262. Kobayashi Y, Colombo A, Akiyama T, Reimers B, Martini G, di Mario C. Modified "T" stenting: a technique for kissing stents in bifurcational coronary lesion. Cathet Cardiovasc Diagn 1998;43:323-6.
263. Schampaert E, Fort S, Adelman AG, Schwartz L. The V-stent: a novel technique for coronary bifurcation stenting. Cathet Cardiovasc Diagn 1996;39:320-6.
264. Baim DS. Is bifurcation stenting the answer? Cathet Cardiovasc Diagn 1996;37:314-6.
265. Colombo A, Stankovic G, Orlic D, Corvaja N, Liistro F, Airoldi F et al. Modified T-stenting technique with crushing for bifurcation lesions: immediate results and 30-day outcome. Catheter Cardiovasc Interv 2003;60:145-51.
266. Pan M, Suarez de Lezo J, Medina A, Romero M, Segura J, Ramirez A et al. A stepwise strategy for the stent treatment of bifurcated coronary lesions. Catheter Cardiovasc Interv 2002;55:50-7.
267. Melikian N, DiMario C. Treatment of bifurcation coronary lesions: a review of current techniques and outcome. J Interven Cardiol 2003;16:507-13.
268. Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martinez J et al. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol 2001;37:51-8.
269. Erratum in: J Am Coll Cardiol 2001;37: 973-4.
270. Ryan TQ. Present-day PTCR versus CABG: a randomized comparison with a different focus and a new result. J Am Coll Cardiol 2001;37:59-62.
271. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP et al.; Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24.
272. The ARTS (Arterial Revascularization Therapies Study). Background, goals and methods. Int J Cardiovasc Intervent 1999;2:41-50.
273. Stent or Surgery Investigators, coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomized controlled trial. Lancet 2002;360:965-70.
274. Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S et al. for the AWESOME co-investigators, percutaneous coronary intervention versus bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcome with bypass: a multicenter, randomized trial. J Am Coll Cardiol 2001;38:143-9.
275. Morrison DA, Sethi G, Sacks, J, Henderson W, Grover F, Sedlis S et al. for the AWESOME co-investigators. Percutaneous coronary intervention versus coronary bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass. The VA AWESOME Multicenter Registry: comparison with the randomized clinical trial. J Am Coll Cardiol 2002;39:266-73.
276. Sedlis SP, Morrison DA, Lorin JD, Esposito R, Sethi G, Sacks J et al.; Investigators of the Dept. of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol 2002;40:1555-66.
277. Rumsfeld JS, Magid DJ, Plomondon ME, Sacks J, Henderson WG, Hlatky M et al. for the VA Angina With Extremely Serious Operative Mortality (AWESOME) Investigators. Quality of life following percutaneous coronary intervention versus coronary bypass surgery in high risk patients with medically refractory ischemia. J Am Coll Cardiol 2003;41: 1732-8.
278. Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis SP et al. for the Investigators of the Department of Veterans Affairs Cooperative Study*385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol 2002;40:1951-4.
279. Sedlis SP, Ramanathan KB, Morrison DA, Sethi G, Sacks J, Henderson WG, for the Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary bypass graft surgery for patients with left ventricular dysfunction, unstable angina and risk factors for adverse outcomes with bypass: outcome of patients in the AWESOME Randomized Trial and Registry. Am J Cardiol 2004;94:1118-20
280. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical epidemiology, a basic science for clinical medicine, 2nd ed. Boston: Little Brown & Co.; 1991.
281. Rothman KJ, Greenland S. Modern epidemiology, 2nd ed. Philadelphia: Lipincott Williams & Wilkins; 1998.
282. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1988;12:529-45.
283. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. Eleven year survival in the Veterans Administrations randomized trial of coronary bypass surgery for stable angina. N Engl J Med 1984;319:332-7.
284. Hennekens CH, Buring JE, editors. Epidemiology in medicine. Boston/Toronto: Little Brown & Co.; 1987.
285. Friedman, Furberg C, DeMets H. Fundamentals of clinical trials, 3rd ed. New York: Springer; 1998
286. Hannan EL, Racz MJ, McCallister BD, Ryan TJ, Arani DT, Isom OW et al. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1999;33:63-72.
287. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005;352:2174-83.
288. Elwood M. Critical appraisal of epidemiological studies and clinical trials, 2nd ed. Oxford: University Press; 1998.
289. Jones RH, Kesler K, Phillips HR 3rd, Mark DB, Smith PK, Nelson CL et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg 1996;111:1013-25.
290. Jones RH, Hannan EL, Hammermeister KE, Delong ER, O'Connor GT, Luepker RV et al. Identification of preoperative variables needed for risk adjustment of short-term mortality after coronary artery bypass graft surgery. The Working Group Panel on the Cooperative CABG Database Project. J Am Coll Cardiol 1996;28: 1478-87.
291. van Domburg RT, Foley DP, Breeman A, van Herwerden LA, Serruys PW. Coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Twenty-year clinical outcome. Eur Heart J 2002;23:543-9.
292. Morrison DA, Veerakul G, Sastravaha K. Cerebrovascular and peripheral vascular comorbidity. In: Morrison DA, Serruys PW, editors. High-risk cardiac revascularization and clinical trials. London: Martin Dunitz; 2002.p.373-86.
293. Roach GW, Kanchuger M, Mangano CM, Newman M, Nussmeier N, Wolman R et al. Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators. N Engl J Med 1996;335: 1857-63.
294. Shaw PJ, Bates D, Carthige NEF, Heaviside D, Julian DG, Shaw DA. Early neurological complications of coronary bypass surgery. Br Med J 1985;291: 1384-7.
295. John R, Choudhri AF, Weinberg AD, Ting W, Rose EA, Smith CR et al. Multicenter review of preoperative risk factors for stroke after coronary artery bypass grafting. Ann Thorac Surg 2000;69:30-5; discussion 35-6.
296. Sotaniemi KA, Mononen H, Hokkanen TE. Long-term cerebral outcome after open-heart surgery. A five-year neuropsychological follow-up study. Stroke 1986;17:410-6.
297. Gardner TJ, Horneffer PJ, Manolio TA, Pearson TA, Gott VL, Baumgartner WA et al. Stroke following coronary artery bypass grafting: a ten-year study. Ann Thorac Surg 1985;40:574-81.
298. Gold JP, Charlson ME, Williams-Russo P, Slatrowski TP, Peterson JC, Pimaglia PA et al. Improvement of outcomes after coronary artery by-pass a randomized trial comparing intraoperative high versus low mean arterial pressure. J Thorac Cardiovasc Surg 1995;110:1302-14.
299. Pugsley W, Klinger L, Paschalis C, Aspey B, Newman MF, Harrison M, Treasure T: Microemboli and Cerebral Impairment During Cardiac Surgery. Vasc Surg 1990;24:34-43.
300. Doblar DD. Cerebrovascular assessment of the high-risk patient: the role of transcranial Doppler ultrasound. J Cardiothorac Vasc Anesth 1996;10:3-14.
301. Yao FSF, Barbut D, Hager DN, Trifiletti RR, Gold JP. Detection of aortic emboli by transesophageal echocardiography during coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1996;10: 314-7.
302. Mariani MA, Boonstra PW, Grandjean JG, John Heijer P. Combining coronary angioplasty with minimally invasive coronary surgery: the "hybrid revascularization". J Invasive Cardiol 1998;10:233-4.
303. Friedrich GJ, Bonathid, Dapent OE. Preliminary experience with minimally invasive coronary artery bypass surgery combined with coronary angioplasty. N Engl J Med 1997;336:1454-5.
304. Clark RE for the committee: Definitions of Terms of the Society of Thoracic Surgeons National Cardiac Surgery Database. Ann Thorac Surg 1994;58:271-3.
305. Edwards FH, Clark RE, Schwartz M. Coronary artery bypass grafting; the society of thoracic surgeons national database experience. Ann Thorac Surg 1994;57:12-9.
306. Hannan EL, Kilburn H, O'Donnell JF, Lukacik G, Shields EP. Adult open heart surgery in New York State: an analysis of risk factors and hospital mortality rates. JAMA 1990;264:2768-74.
307. Hannan EL, Kilburn H, Racz M, Shields E, Chassin MR. Improving the outcomes of coronary 'artery bypass surgery in New York State. JAMA 1994;271: 761-6.
308. Higgins TL, Estafanous FG, Loop FD, Beck GJ, Blum JM, Paranandi L. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients: a clinical severity score. JAMA 1992;267:2344-8.
309. Weiman D, Ramanathan K, Morrison DA. Chronic pulmonary disease. In: Morrison DA, Serruys PW, editors. High-risk cardiac revascularization and clinical trials. London: Martin Dunitz; 2002.p.363-372.
310. Kennedy JW and the Registry committee of the Society for Cardiac Angiography. Complications associated with cardiac catheterizatlon and angiography. Cathet Cardiovasc Dig 1982;8:5-11.
311. Davis K, Kennedy JW, Kemp HG Jr, Judkins MP, Gosselin AJ, Killip T. Complications of coronary arteriography from the Collaborative Study of Coronary Artery Surgery (CASS). Circulation 1979;59:1105-12.
312. Krone RJ, Johnson L, Noto T, and the Registry Committee of the Society for Cardiac Angiography and Interventions. Five year trends in cardiac catheterization. Cathet Cardiovasc Diag 1996;39:31-5.
313. Chandrasekar B, Doucet S, Bilodeau L, Crepeau J, deGuise P, Gregoire J et al. Complications of cardiac catheterization in the current era: a single-center experience. Catheter Cardiovasc Interv 2001;52:289-95.
314. Hong MK, Popma JJ, Baim DS, Yeh W, Detre KM, Leon MB. Frequency and predictors of major in-hospital ischemic complications after planned and unplanned new-device angioplasty from the New Approaches to Coronary Intervention (NACI) registry. Am J Cardiol 1997;80:40K-49K.
315. Kiemeneij F, Laarman GJ, Odekerken D, Slagboom T, van der Wieken R. A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the access study. J Am Coll Cardiol 1997;29:1269-75.
316. Block PC, Peterson ED, Krone R, Kesler K, Hannan E, O'Connor GT et al. Identification of variables needed to risk adjust outcomes of coronary interventions: evidence-based guidelines for efficient data collection. J Am Coll Cardiol 1998;32:275-82.
317. Erratum in: J Am Coll Cardiol 1999;34:613. Peterson EC [corrected to Peterson ED].
318. Holmes DR, Selzer F, Johnston JM, Kelsey SF, Holubkov R, Cohen HA et al.; National Heart, Lung, and Blood Institute Dynamic Registry. Modeling and risk prediction in the current era of interventional cardiology: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. Circulation 2003;107:1871-6.
319. Bergelson BA, Jacobs AK, Cupples LA, Ruocco NA Jr, Kyller MG, Ryan TJ et al. Prediction of risk for hemodynamic compromise during percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;70: 1540-5.
320. Ellis SG, Myler RK, King SB 3rd, Douglas JS Jr, Topol EJ, Shaw RE et al. Causes and correlates of death after unsupported coronary angioplasty: implications for use of angioplasty and advanced support techniques in high-risk settings. Am J Cardiol 1991;68:1447-51.
321. Tenaglia AN, Fortin DF, Califf RM, Frid DJ, Nelson CL, Gardner L et al. Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. J Am Coll Cardiol 1994;24:1004-11.
322. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 1999;100:2400-5.
323. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatinine kinase-MB elevation after coronary intervention. Circulation 2002;106:1205-10.
324. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-51.
325. Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol 2000;36:22-4.
326. Heusch G, Schulz R, Baumgart D, Haude M, Erbel R. Coronary microembolization. Prog Cardiovasc Dis 2001;44:217-30.
327. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994;89:2514-8.
328. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996;39:113-8.
329. Klein LW, Kern MJ, Berger P, Sanborn T, Block P, Babb J et al.; Interventional Cardiology Committee of the Society of Cardiac Angiography and Interventions. Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2003;60:194-201.
330. Baim DS, Carrozza JP Jr. Understanding the "no-reflow" problem. Cathet Cardiovasc Diagn 1996;39: 7-8.
331. Wilson RF, Lesser JR, Laxson DD, White CW: Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989;807-11.
332. Pomerantz RM, Kuntz RE, Diver DJ, Safian RD, Baim DS. Intracoronary verapamil for the treatment of distal microvascular coronary artery spasm following PTCA. Cathet Cardiovasc Diagn 1991;24:283-5.
333. Assali AR, Sdringola S, Ghani M, Denkats AE, Yepes A, Hanna GP et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovasc Interv 2000;51:27-31; discussion 32.
334. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002;57:444-51.
335. Fischell TA, Carter AJ, Foster MT, Hempsall K, DeVries J, Kim DH et al. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998;45:360-5.
336. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE et al.; Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-90,
337. Grube E, Gerckens U, Yeung AC, Rowold S, Kirchhof N, Sedgewick J et al. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation 2001;104:2436-41.
338. Stone GW, Rogers C, Ramee S, White C, Kuntz RE, Popma JJ et al. Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy. J Am Coll Cardiol 2002;40:1882-8.
339. Popma JJ, Cox N, Hauptmann KE, Reifart N, Virmani R, Emira K et al. Initial clinical experience with distal protection using the filter-wire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention. Cathet Cardiovasc Interv 2002;57:125-34.
340. Cohen BM, Weber YJ, Reisman M, Casale A, Dorros G. Coronary perforation complicating rotational ablation: the U.S. multicenter experience. Cathet Cardiovasc Diagn 1996;Suppl 3:55-9.
341. Bittl JA, Ryan TJ, Keaney JF Jr, Tcheng JE, Ellis SG, Isner JM et al. for the Percutaneous Excimer Laser Coronary Angioplasty Registry. Coronary artery perforation during excimer laser coronary angioplasty. J Am Coll Cardiol 1993;21:1158-65.
342. Holmes DR, Reeder GS, Ghazzal ZMB, Bresnahan JF, King SB III, Leon MB et al. Coronary perforation after excimer laser coronary angioplasty: the Excimer Laser Coronary Angioplasty Registry Experience. J Am Coll Cardiol 1994;23:330-5.
343. Briguori C, Nishida T, Anzuini A, DiMario C, Grube E, Columbo A. Emergency polytetrafluoroethylene-covered stent implantation to treat coronary ruptures. Circulation 2000;102:3028-31.
344. Gercken U, Lansky AJ, Buellesfeld L, Desai K, Badereldin M, Mueller R et al. Results of the Jostent coronary stent graft implantation in various clinical setting: procedural and follow-up results. Cathet Cardiovasc Interv 2002;56:353-60.
345. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50, 310-8.
346. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73:418-27.
347. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation 1985;71:699-708.
348. Mann JM, Davies MJ. Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. Circulation 1996;94:928-31.
349. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
350. Reimer KA, Lowe JE, Rasmussen MA, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977;56:786-94.
351. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633-44.
352. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-5.
353. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62.
354. Ambrose JA, Winters SL, Stern A, Eng A, Teichholz LE, Gorlin R et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985;5:609-16.
355. Smith SC Jr, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ et al. AHA consensus panel statement. Preventing heart attack and death in patients with coronary disease. The Secondary Prevention Panel. J Am Coll Cardiol 1995;26:292-4.
356. 27th Bethesda Conference: Matching the intensity of risk factor management with the Hazard for Coronary Disease Events; September 14-15, 1995. J Am Coll Cardiol 1996;27:957-1047.
357. Pearson T, Rapaport E, Criqui M, Furberg C, Fuster V, Hiratzka L et al. Optimal risk factor management in the patient after coronary revascularization. AHA Medical/ Scientific Statement. Circulation 1994;90:3125-33.
358. Smith SC Jr. Clinical treatment of dyslipidemia: practice patterns and missed opportunities. Am J Cardiol 2000;86 Suppl:62L-65L.
359. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999;20:58-69.
360. Smith SC Jr, Allen J, Blair SP, Bonow RO, Brass LM, Fonarow GC et al. AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease; 2006 update. J Am Coll Cardiol 2006;47:2130-9.
361. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention pilot results. Arch Intern Med 2004;164:203-9.
362. Mehta RH, Montoye CK, Gallogy M, Baker P, Blount A, Faul J et al. Improving quality of care for acute myocardial infarction The Guidelines Applied in Practice (GAP) Initiative. JAMA 2002;287:1269-76.
363. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation 2002;106:516-20.
364. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine. Part II. Circulation 2002;106:626-30.
365. Hlatky MA. Economic comparisons of coronary angioplasty and coronary bypass surgery. In: Weintraub WS, editor. Contemporary cardiology: cardiovascular health care economics. Totowa, NJ: Humana Press; 2003.p.223-32.
366. Cohen DJ, Krumholz HM, Sukin CA, Ho KKL, Siegrist RB, Clemen M et al. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Circulation 1995;92:2480-7.
367. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJRM, Schönberger JPAM et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24.
368. Weintraub WS, Mahoney EM, Zhang Z, Chu H, Hutton J, Buxton M et al. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart 2004;90: 782-8.
369. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses. Results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial. Circulation 2004;110:508-14.
370. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B et al.; BARI Investigators. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N Engl J Med 1997;336:92-9.
371. Stroupe KT, Morrison DA, Hlatky MA, Barnett PG, Cao L, Lyttle C et al. for the Investigators of Veterans Affairs Cooperative Study #385 (AWESOME). Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation. In press 2006.
372. Claude J, Schindler C, Kuster GM, Schwenkglenks M, Szucs T, Buser P et al.; Trial of Invasive versus Medical therapy in the Elderly (TIME) Investigators. Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J 2004;25:2195-203.
373. Morrison DA. Cardiac revascularization of the medically refractory elderly patient: it is TIME to pay the piper. Eur Heart J 2004;25:2180-2.
374. Klein LW. Are drug-eluting stents the preferred treatment for multivessel coronary artery disease? J Am Coll Cardiol 2006;47:22-6.
375. Valgimigli M, Malagutti P, Aoki J, Garcia-Garcia HM, Rodriguez Granillo GA, van Mieghem CA et al. Sirolimus-eluting versus paclitaxel-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: a combined RESEARCH and T-SEARCH long-term analysis. J Am Coll Cardiol 2006;47:507-14.
376. Lee MS, Kapoor N, Jamal F, Czer L, Aragon J, Forrester J et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2006;47:864-70.